I am an Associate Professor of Medicine and Epidemiology and physician scientist at the University of Pennsylvania. I lead a highly active NIH-funded translational research program in cardio-oncology and am the PI of multiple investigator-initiated cohort studies and clinical trials focused on the study of the cardiotoxic effects of doxorubicin, trastuzumab, sunitinib, and radiation therapy in breast, renal cell, and lung cancers, and lymphoma patients. My overarching scientific objectives are to understand how we can improve cardiovascular outcomes in cancer patients by determining and modifying individual patient risk, through detailed phenotyping of clinical characteristics, biologic markers, and echocardiography-derived measures of myocardial mechanics and function.

I serve as the Director for the Penn Center for Quantitative Echocardiography and am the founding Director of the Penn Cardio-Oncology Center of Excellence.  I am an invited member of many cardio-oncology expert consensus and research groups within the NIH, FDA, American Society of Clinical Oncology, American College of Cardiology, American Heart Association, and European Society of Cardiology focused on advancing our understanding of cardiovascular disease in the growing cancer population. I serve as the Inaugural Editor-in-Chief of JACC: CardioOncology and am on the Editorial Board of Circulation, Circulation Heart Failure and the Journal of the American College of Cardiology.  I am a member of the Sarnoff Cardiovascular Research Foundation Scientific Committee and an inducted member of the American Society of Clinical Investigation.